PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 14498/PTQ

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 1

Complete if Known	
Application Number	09/430,966
Filing Date	11/01/1999
First Named Inventor	Bart DE CORTE
Group Art Unit	1624
Examiner Name	VENKATARAMAN BALASUBRAMANIAN
Attorney Docket Number	JAB 1425

		OTHER - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate).		
Examiner's Initials*	Cite No.1	title of the item (book, magazine, journal, serial, symposium, catalog, etc.), dale, page(s), volume-issue number(s), publisher, city and/or country where published	Translation	T <sup>2</sup>
		VINGERHOETS, Antiviral activity TMC 125 SDM, CROI, San Francisco, Feb. 2004	No	
,		ARNOLD, Conformational Flexibility of DAPYs: activity against resistant HIV, Aug. 2003	No .	
		VINGERHOETS, Resistance before/after therapy - TMC 125C207, XII Resistance Mexico, June 2003	No	
		VINGERHOETS, Resistance profile clinical isolates TMC 125, XII Resistance Mexico, June 2003	No :	
•		GAZZARD, TMC 125 C207 study treatment-experienced, CROI Seattle, Feb. 2002	No	
	<del> </del>	LANGE, TMC 125 decay rate vs ERA, CROI Seattle, Feb, 2002	No	1
	<del> </del>	GAZZARD, 7 day treatment-experienced, WAC Barcelona, Jul. 2002	No	1
	<b> </b>	LEWI, Potency & multiple binding modes of TMC 125, CROI Boston, Feb. 2003	No	<del>                                     </del>
	<b></b>	M-P de BETHUNE. TMC 125 resistance profiles. Resistance, Mexico, June 2003	No	<del>                                     </del>
		VINGERHOETS, TMC 125-C207 resistance analysis, Resistance, Mexico, June 2003	No	
		TMC 125 for 7 days in HIV-1+ individuals with NNRTI resistance (TMC 125- C207), AIDS, 17(18): F49-54, Dec. 5, 2003	No	
		TMC 125 as 7d monotherapy in ARV-naive subjects (TMC 125-C208), AIDS, 17(17): 2487-2494, Nov. 21, 2003	No	
		TMC 125 similar potency to 5-drug, 3-class regimen, AIDS, 17(18): 2623-2627Dec. 5, 2003	No	
		UDIER-BLAGOVIC, Validation of a model for the complex of HIV-1 reverse transcriptase with nonnucleoside inhibitor TMC125, Journal of American Chemical Society, 2003, 125(20), pp.6016-6017	No	
	·	GULICK, New Antiretroviral drugs, Clinical Microbiology and Infection, 2003, 9(3), pp 186-193	No	
		LUDOVICI, Evolution of enti-HIV drug candidates. Part 3: diarylpyrimidine, (DAPY)analogues.Bioorganic & Medicinal Chemstry Letters (2001), 11(17), pp. 2235-2239.	No	
	ļ		ļ	+
	<b> </b>			-
· · · · · · · · ·	<del></del>			<u> </u>
				-
				<del> </del>
	<del> </del>			<del>                                     </del>
	├		<del></del>	_
	<b>—</b> —			1

Examiner	Date		
Signature	Conside	rred	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patient Documents at <a href="https://www.uspto.gov">www.uspto.gov</a>, or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Sind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English tanguage Translation is attached.

Docket No. JAB 1425

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Bart DE CORTE et al.

Serial No.: 09/430,966 Art Unit: 1624

Filed : 11/01/1999


Examiner: VENKATARAMAN

BALASUBRAMANIAN

For

: HIV REPLICATION INHIBITING PYRIMIDINES

I hereby certify that this correspondence is being transmitted via facsimile to: Commissioner for Fatents, PO Box 1450, Alexandria, VA 22313-1450



Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

## SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This copy is supplemental to the First Information Disclosure Statement mailed on August 11, 2003.

Pursuant to 37 C.F.R. \$1.56 and in accordance with 37 C.F.R. \$\$1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. \$1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this

information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under \$1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in \$1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under \$1.114, no additional fee is required.

In accordance with \$1.129(a), this Information
Disclosure Statement is being filed in connection with [ ] the
first or _second After Final Submission, therefore:
Statement in Accordance with \$1.97(e)
(attached); or
Please charge Deposit Account No. 10-
0750/ / the fee of \$180.00 as set forth
in \$1.17(p).
☐ In accordance with \$1.97(c), this Information
Disclosure Statement is being filed after the period set forth
in \$1.97(b) above but before the mailing date of either a Final
Action under \$1.113 or a Notice of Allowance under \$1.311, or
an action that otherwise closes prosecution and that it is
accompanied by one of:

	Statement in Accordance with \$1.97(e)
	(attached); or
	Please charge Deposit Account No. 10-
	0750/ / the fee of \$180.00 as set forth
	in \$1.17(p).
In a	ccordance with \$1.97(d), this Information
Disclosure Stat	ement is being filed after the mailing date of
either a Final	Action under \$1.113 or a Notice of Allowance
under \$1.311 k	out before the payment of the Issue Fee.
Applicant(s) he	ereby petition(s) for consideration of this
Information Dis	sclosure Statement. Included are: Statement in
Accordance with	1 \$1.97(e) as set forth below and the fee of
\$180.00 as set	forth in \$1.17(p).
<u> </u>	
	es of each of the references listed on the
attached Form E	TO-1449 are enclosed herewith.
⊠ Copie	es of references listed on the attached Form PTO
_	ed herewith EXCEPT THAT: References contained in
	are not enclosed in this facsimile will be sent
	to the Examiner.
	In view of the voluminous nature of references
	[list as appropriate], and the likelihood that
	these references are available to the Examiner,
	copies are not enclosed herewith.
	•
	If any of the foregoing publications are not
	available to the Examiner, Applicant will
	endeavor to supply copies at the Examiner's
	request.
X There	are no listed references which are not in the

English language.

The relevance of those listed references which	are
not in the English language is as follows:	
Attached are copies of search report(s) from	
corresponding patent application(s), which are listed on	the
attached Submission Under MPEP 609 D.	
Copies of the references listed on the search	
report(s) are included except for those previously cited	in a
IDS mailed .	
Attached are the following non-published pending	ıg
patent applications which may be deemed relevant, which a	re
listed on the attached Submission Under MPEP 609 D.	

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/JAB 1425/JJiT. This form is submitted in triplicate.

Respectfully submitted,

Jesus Juanos i Timoneda Reg. No. 43,332 Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-1513
DATED: January 23, 2004